Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07218770 | A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants | PHASE1 | ACTIVE NOT_RECRUITING | 72 | — | — | Dec 17, 2025 | Jun 28, 2028 | Apr 22, 2026 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| Sequential Single Ascending Dose Cohorts | EXPERIMENTAL | - |
| Sequential Multiple Ascending Dose Cohorts | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN7041 | DRUG | Administered as per the protocol |
Key Inclusion Criteria: 1. Diagnosis of non-infectious anterior, intermediate, posterior or panuveitis (For anterior uveitis, there must be evidence of inflammation affecting the posterior segment), as defined in the protocol 2. Active disease at baseline, as defined in the protocol 3. Part A only:...